Which has the lower trailing P/E, KNSA or SHC?

SHC has the lower trailing P/E: KNSA trades at 77.10 and SHC at 32.23. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, KNSA or SHC?

Over the past five years, KNSA grew revenue faster — KNSA at a 155.66% CAGR versus SHC at 6.66%.

Is KNSA or SHC more profitable?

SHC runs the higher net margin — KNSA at 9.59% versus SHC at 13.44%.

How have KNSA and SHC total returns compared?

Over the past 5 years, KNSA delivered 47.48% and SHC delivered -6.39% annualized total return. Past performance doesn't predict future results.

Kiniksa Pharmaceuticals International, plc (KNSA) vs Sotera Health Company (SHC)

A side-by-side comparison of Kiniksa Pharmaceuticals International, plc and Sotera Health Company across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

KNSA

Kiniksa Pharmaceuticals International, plc

$5.76B

$75.56HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT

SHC

Sotera Health Company

$5.26B

$18.45HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT

Total return — KNSA vs SHC

growth of $100 · dividends reinvested · last 6y

KNSA +415.6% (+31.4%/yr)SHC -26.1% (-4.9%/yr)KNSA compounded faster over this window

Log scale — wide-divergence pair

KNSA SHC

KNSA vs SHC: by the numbers

•KNSA is the larger company ($5.76B vs $5.26B market cap).
•SHC trades at the lower trailing earnings multiple (32.23 vs 77.10 P/E), one valuation lens rather than an overall verdict.
•SHC converts more revenue to profit (13.44% vs 9.59% net margin).
•KNSA grew revenue faster over the past five years (155.66% vs 6.66% CAGR).

Metrics side by side

Valuation

Metric	KNSA	SHC
P/E ratio	77.10	32.23
Forward P/E	54.25	18.74
P/S ratio	6.85	4.33
P/B ratio	8.80	7.90
EV / EBITDA	54.79	12.52
FCF yield	3.18%	2.14%

Profitability

Metric	KNSA	SHC
Gross margin	54.49%	54.72%
Operating margin	11.92%	36.24%
Net margin	9.59%	13.44%
ROE	12.33%	24.56%
ROIC	9.76%	8.80%

Growth (annualized)

Metric	KNSA	SHC
Revenue CAGR (5Y)	155.66%	6.66%
FCF CAGR (5Y)	N/A	17.34%
Total return CAGR (5Y)	47.48%	-6.39%

Frequently asked

Which has the lower trailing P/E, KNSA or SHC?: SHC has the lower trailing P/E: KNSA trades at 77.10 and SHC at 32.23. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, KNSA or SHC?: Over the past five years, KNSA grew revenue faster — KNSA at a 155.66% CAGR versus SHC at 6.66%.
Is KNSA or SHC more profitable?: SHC runs the higher net margin — KNSA at 9.59% versus SHC at 13.44%.
How have KNSA and SHC total returns compared?: Over the past 5 years, KNSA delivered 47.48% and SHC delivered -6.39% annualized total return. Past performance doesn't predict future results.

Go deeper

Full KNSA analysis Full SHC analysis Interactive comparison tool

Dig into the metrics

Kiniksa Pharmaceuticals International P/E ratio Sotera Health P/E ratio Kiniksa Pharmaceuticals International ROE Sotera Health ROE Kiniksa Pharmaceuticals International operating margin Sotera Health operating margin Kiniksa Pharmaceuticals International revenue growth Sotera Health revenue growth Kiniksa Pharmaceuticals International free cash flow Sotera Health free cash flow

Kiniksa Pharmaceuticals International & Sotera Health appear in these rankings

Fastest Revenue Growth Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.